• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    AirSculpt Technologies Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    12/17/24 7:01:49 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care
    Get the next $AIRS alert in real time by email
    false 0001870940 0001870940 2024-12-16 2024-12-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT 

    Pursuant to Section 13 or 15(d) of 
    The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): December 16, 2024

     

    AirSculpt Technologies, Inc.

    (Exact name of Registrant as specified in its charter)

     

    Delaware

    (State or other jurisdiction of 
    incorporation)

    001-40973

    (Commission File Number)

    87-1471855

    (IRS Employer

    Identification No.)

     

    1111 Lincoln Road, Suite 802
    Miami Beach, FL 33139

    (Address of principal executive offices, including zip code)

     

    (786) 709-9690

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered or to be registered pursuant to Section 12(b) of the Act.

     

    Title of each class   Trading
    Symbol(s)
      Name of each exchange on
    which registered
    Common Stock, $0.001 par value per share   AIRS   The Nasdaq Global Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

     

     

     

     

     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

     

    Appointment of New Chief Executive Officer

     

    On December 17, 2024, AirSculpt Technologies, Inc. (the “Company”) announced that it has hired Yogesh Jashnani, 43, to serve as the Company’s Chief Executive Officer, effective January 7, 2025. Prior to joining the Company, Mr. Jashnani served as the Chief Revenue Officer of Sky Zone, Inc. from November 2023 to January 2025 (and as a consultant in the same role from April 2023 to November 2023), and as Chief Commercial Officer of Ideal Image Development Corp., from December 2019 to March 2023. Mr. Jashnani received his B.E. from the University of Mumbai and his M.S. from the University of Wisconsin-Madison.

     

    There are no arrangements or understandings between Mr. Jashnani and any other person pursuant to which he was selected as an executive officer of the Company, and there are no family relationships between Mr. Jashnani and any of the Company’s directors or executive officers. Mr. Jashnani has no direct or indirect material interest in any existing or currently proposed transaction that would require disclosure under Item 404(a) of Regulation S-K.

     

    In connection with his appointment as Chief Executive Officer of the Company, Mr. Jashnani will receive the following compensation:

     

    ·Annual base salary equal to $700,000;
    ·Eligibility to earn an annual target cash performance bonus of 100% of Mr. Jashnani’s annual base salary for each fiscal year during Mr. Jashnani’s term;
    ·Eligibility to receive reimbursement of any reasonable relocation or moving expenses incurred by Mr. Jashnani in the event that the Company requires Mr. Jashnani to relocate his principal office location to the Company’s principal office, up to a maximum of $175,000;
    ·A sign-on cash bonus equal to $262,500 with $150,000 paid on signing and the remainder paid when annual bonuses are paid to the Company’s executive officers;
    ·A sign-on equity award with a grant value of $2,333,333, consisting of restricted stock units (“RSUs”) with a grant date value of $1,000,000 (vesting annually over three years) and of performance-based restricted stock units (“PSUs”) with a grant date value of $1,333,333, which will be eligible to vest over a three-year period based on stock price appreciation from the grant date, as measured by a sixty-day volume-weighted average price (“VWAP”) as follows: 25% of the PSU stock price goal is met when the 60-day VWAP is at least 125% of grant date stock price; 50% of the PSU stock price goal is met when the 60-day VWAP is at least 175% of grant date stock price; 75% of the PSU stock price goal is met when the 60-day VWAP is at least 200% of grant date stock price; and 100% of the PSU stock price goal is met when the 60-day VWAP is at least 225% of grant date stock price. The number of RSUs and PSUs to be granted to Mr. Jashnani will be based on (i) the applicable grant date value above divided by (ii) the per share closing price of the Company’s common stock on the grant date;
    ·Eligibility to participate in the Company’s 2021 Equity Incentive Plan, with a 2025 annual equity award having a grant date value of 200% of Mr. Jashnani’s annual base salary on terms substantially similar to the Company’s other executive officers, subject to the terms and conditions of the applicable grant agreement and the approval of the Board of Directors of the Company (the “Board”); and
    ·Eligibility in the Company’s standard benefits program.

     

    In addition, Mr. Jashnani is entitled to the following severance benefits upon a termination without “cause” or resignation for “good reason” (in addition to any accrued benefits at the time of termination), subject to Mr. Jashnani’s execution, and non-revocation, or a general release of claims in favor of the Company:

     

    ·If such termination without “cause” or resignation for “good reason” occurs more than 3 months prior to, or 12 months following, a change in control:

     

    oContinued payment of Mr. Jashnani’s base salary for 12 months immediately following termination;
    oPayment of a prorated annual bonus for the year of termination based on actual performance when other Company executives are paid annual bonuses;

     

     

     

     

    oMonthly payments equal to the cost of COBRA coverage for Mr. Jashnani and eligible dependents for 12 months following termination;
    o12 months of vesting acceleration for unvested RSUs which remain outstanding upon termination under the sign-on equity award and 2025 annual equity award; and
    oProration of the number of PSUs under the sign-on equity award and 2025 annual equity award based on the number of days that Mr. Jashnani was employed during the applicable performance period, which will vest based on actual performance achievement at the end of the applicable performance period.

     

    ·If such termination without “cause” or resignation for “good reason” occurs within 3 months prior to, or 12 months following, a change in control:

     

    oA lump sum payment equal to 1.5 times the sum of Mr. Jashnani’s base salary and target annual bonus;
    oMonthly payments equal to the cost of COBRA coverage for Mr. Jashnani and eligible dependents for 18 months following termination (unless Mr. Jashnani becomes eligible for medical coverage under a new employer’s plan or COBRA coverage ceases prior to such date);
    oFull vesting acceleration for unvested RSUs which remain outstanding upon termination under all of Mr. Jashnani’s equity awards; and
    oConversion of all outstanding PSUs under all of Mr. Jashnani’s equity awards upon a change in control into time-based RSUs at the greater of target and actual performance through the date of such change in control, which will vest in full at the end of the performance period, or if earlier, upon Mr. Jashnani’s termination without cause or resignation for good reason within 3 months prior to, or 12 months following, following a change in control.

     

    Further, Mr. Jashnani is subject to non-competition, non-solicitation and confidentiality covenants.

     

    The foregoing description is qualified in its entirety by reference to the full and complete terms of Mr. Jashnani’s Employment Agreement, dated December 6, 2024, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

     

    Return of Dennis Dean to Full Time Duties as Chief Financial Officer

     

    Dennis Dean will continue to serve as the Interim Chief Executive Officer of the Company until the commencement of Mr. Jashnani’s employment with the Company on January 7, 2025, at which time Mr. Jashnani will succeed Mr. Dean as Chief Executive Officer of the Company and Mr. Dean will continue his full-time duties as Chief Financial Officer of the Company.

     

    Director Appointment

     

    Effective January 7, 2025, the Board of the Company appointed Mr. Jashnani to serve as a director of the Company. Mr. Jashnani will stand for election by stockholders at the Company’s 2025 annual meeting of stockholders.

     

    Item 7.01. Regulation FD Disclosure.

     

    On December 17, 2024, the Company issued a press release announcing the appointment of Mr. Jashnani as Chief Executive Officer and director of the Company. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

     

    In accordance with General Instruction B.2 of Form 8-K, the information furnished under this Item 7.01, including Exhibit 99.1, will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in that filing.

     

     

     

     

    Item 9.01.  Financial Statements and Exhibits.

     

    (d) Exhibits. 

     

    10.1 Employment Agreement between the Company and Yogesh Jashani, dated December 6, 2024
    99.1 Press Release, dated December 17, 2024
    104  Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      AirSculpt Technologies, Inc.
       
    Date: December 17, 2024 By: /s/ Dennis Dean
      Name: Dennis Dean
      Title: Interim Chief Executive Officer and Chief Financial Officer

     

     

     

    Get the next $AIRS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIRS

    DatePrice TargetRatingAnalyst
    10/17/2024Neutral
    BTIG Research
    5/14/2024$8.25 → $5.00Outperform → Market Perform
    Leerink Partners
    11/11/2022$4.00Overweight → Neutral
    Piper Sandler
    6/16/2022$17.00 → $8.50Overweight → Equal-Weight
    Morgan Stanley
    11/23/2021$18.00Outperform
    Raymond James
    11/23/2021$17.00Overweight
    Morgan Stanley
    11/23/2021$26.00Outperform
    SVB Leerink
    11/23/2021$22.00Overweight
    Piper Sandler
    More analyst ratings

    $AIRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by AirSculpt Technologies Inc.

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    3/11/26 5:30:58 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    Large owner Chernett Jorey bought $91,200 worth of shares (45,600 units at $2.00), increasing direct ownership by 0.72% to 6,398,211 units (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    3/9/26 8:40:24 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    Large owner Chernett Jorey bought $192,900 worth of shares (110,000 units at $1.75), increasing direct ownership by 2% to 6,352,611 units (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    3/4/26 6:58:41 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AirSculpt Technologies Appoints Mike Doyle as Non-Executive Chairman of the Board

    MIAMI BEACH, Fla., Nov. 17, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced the appointment of Mike Doyle as the Non-Executive Chairman of its Board of Directors. Mr. Doyle brings over 30 years of leadership experience in the multi-center healthcare sector. He also serves on several boards where he is recognized for both operating experience and strategic expertise. Yogi Jashnani, CEO of AirSculpt, commented, "Mike has helped to build several successful multi-site healthcare organizations with great experience partnering with surgeons while developing new centers

    11/17/25 5:32:51 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies Reports Third Quarter Fiscal 2025 Results

    MIAMI BEACH, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced results for the third quarter ended September 30, 2025. Yogi Jashnani, Chief Executive Officer, stated: "During the quarter, we made strong progress on our key initiatives that focused on new growth opportunities, margin improvement, and debt reduction. While third quarter revenue was lower than anticipated, this is reflective of timing, instead of the trajectory of our business. We see a broader market opportunity ahead driven by the structural shift in the aesthetics space due to GLP-1 us

    11/7/25 6:00:00 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies Announces Third Quarter Fiscal 2025 Earnings Release Date and Conference Call

    MIAMI BEACH, Fla., Oct. 31, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. ("AirSculpt") (NASDAQ:AIRS) an industry leader and provider of premium body contouring procedures, today announced it will report third quarter 2025 financial results before market open on Friday, November 7, 2025, to be followed by a conference call on the same day at 8:30 a.m. Eastern Time. The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13756042 or by clicking this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Air

    10/31/25 6:45:00 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Chernett Jorey bought $91,200 worth of shares (45,600 units at $2.00), increasing direct ownership by 0.72% to 6,398,211 units (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    3/9/26 8:40:24 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    Large owner Chernett Jorey bought $192,900 worth of shares (110,000 units at $1.75), increasing direct ownership by 2% to 6,352,611 units (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    3/4/26 6:58:41 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    Director Feinstein Adam T bought $4,000,000 worth of shares (1,000,000 units at $4.00) (SEC Form 4)

    4 - Airsculpt Technologies, Inc. (0001870940) (Issuer)

    6/11/25 5:06:44 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by AirSculpt Technologies Inc.

    SCHEDULE 13G/A - Airsculpt Technologies, Inc. (0001870940) (Subject)

    2/13/26 6:44:35 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by AirSculpt Technologies Inc.

    SCHEDULE 13G/A - Airsculpt Technologies, Inc. (0001870940) (Subject)

    11/14/25 6:07:40 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    SEC Form 10-Q filed by AirSculpt Technologies Inc.

    10-Q - Airsculpt Technologies, Inc. (0001870940) (Filer)

    11/7/25 4:37:23 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    Financials

    Live finance-specific insights

    View All

    AirSculpt Technologies Reports Third Quarter Fiscal 2025 Results

    MIAMI BEACH, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced results for the third quarter ended September 30, 2025. Yogi Jashnani, Chief Executive Officer, stated: "During the quarter, we made strong progress on our key initiatives that focused on new growth opportunities, margin improvement, and debt reduction. While third quarter revenue was lower than anticipated, this is reflective of timing, instead of the trajectory of our business. We see a broader market opportunity ahead driven by the structural shift in the aesthetics space due to GLP-1 us

    11/7/25 6:00:00 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies Announces Third Quarter Fiscal 2025 Earnings Release Date and Conference Call

    MIAMI BEACH, Fla., Oct. 31, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. ("AirSculpt") (NASDAQ:AIRS) an industry leader and provider of premium body contouring procedures, today announced it will report third quarter 2025 financial results before market open on Friday, November 7, 2025, to be followed by a conference call on the same day at 8:30 a.m. Eastern Time. The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13756042 or by clicking this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Air

    10/31/25 6:45:00 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies Announces Second Quarter Fiscal 2025 Earnings Release Date and Conference Call

    MIAMI BEACH, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. ("AirSculpt") (NASDAQ:AIRS), an industry leader and provider of premium body contouring procedures, today announced it will report second quarter 2025 financial results before market open on Friday, August 1, 2025, to be followed by a conference call on the same day at 8:30 a.m. Eastern Time. The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13754561 or by clicking this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Air

    7/25/25 6:45:00 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on AirSculpt Technologies

    BTIG Research initiated coverage of AirSculpt Technologies with a rating of Neutral

    10/17/24 7:13:51 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded AirSculpt Technologies from Outperform to Market Perform and set a new price target of $5.00 from $8.25 previously

    5/14/24 7:53:44 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    AirSculpt Technologies downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded AirSculpt Technologies from Overweight to Neutral and set a new price target of $4.00

    11/11/22 3:44:11 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    Leadership Updates

    Live Leadership Updates

    View All

    AirSculpt Technologies Names Yogi Jashnani Chief Executive Officer

    MIAMI BEACH, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS) ("AirSculpt" or the "Company"), an industry leader and provider of premium body contouring procedures, today announced the appointment of Yogi Jashnani as Chief Executive Officer ("CEO") and a member of the Board of Directors. He succeeds Dennis Dean, Interim Chief Executive Officer and Chief Financial Officer who will continue as Chief Financial Officer, all effective January 7, 2025. A highly-talented, results oriented executive with an accomplished career spanning more than two decades, Mr. Jashnani has architected successful transformations for public and private companies in the aesthetics

    12/17/24 6:45:00 AM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    $AIRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by AirSculpt Technologies Inc.

    SC 13G/A - Airsculpt Technologies, Inc. (0001870940) (Subject)

    11/8/24 8:42:05 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G/A filed by AirSculpt Technologies Inc. (Amendment)

    SC 13G/A - Airsculpt Technologies, Inc. (0001870940) (Subject)

    2/14/24 1:11:48 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G filed by AirSculpt Technologies Inc.

    SC 13G - Airsculpt Technologies, Inc. (0001870940) (Subject)

    4/27/23 9:49:49 PM ET
    $AIRS
    Medical/Nursing Services
    Health Care